An overview of the diagnosis and treatment of erectile dysfunction

Drugs

Volumn 66, Issue 18, 2006, Pages 2339-2355

  Sivalingam, Sivaprakasam ^a,b   Hashim, Hashim ^a   Schwaibold, Hartwig ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ANDROGEN; APOMORPHINE; CAVERJET; DIHYDROERGOTOXINE; ERYTHROMYCIN; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; KETOCONAZOLE; NICORANDIL; NITRATE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; PROSTAVASIN; PROTEINASE INHIBITOR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACNE; AGING; ALCOHOL CONSUMPTION; ANAMNESIS; ANDROGEN THERAPY; ANXIETY; ARTHRITIS; ATHEROSCLEROSIS; BACKACHE; BEHAVIOR THERAPY; BLURRED VISION; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COLOR VISION DEFECT; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DIZZINESS; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; ECONOMIC EVALUATION; EPILEPSY; ERECTILE DYSFUNCTION; FLUSHING; FOLLOW UP; FOOD; FOOD DRUG INTERACTION; GYNECOMASTIA; HEADACHE; HEMATOCRIT; HEMOCHROMATOSIS; HEPATITIS; HIRSUTISM; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOGONADISM; HYPOTENSION; INDIGESTION; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOCAL SKIN REACTION; META ANALYSIS; MYALGIA; NAUSEA; OBSTRUCTIVE JAUNDICE; PATIENT REFERRAL; PELIOSIS HEPATIS; PELVIC FLOOR MUSCLE TRAINING; PENIS PROSTHESIS; PERIPHERAL EDEMA; PEYRONIE DISEASE; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOANALYSIS; PSYCHOEDUCATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REVIEW; RHINITIS; RISK FACTOR; SEXUALITY; SIDE EFFECT; SMOKING; SOMNOLENCE; SPINE INJURY; SYSTEMATIC REVIEW; THYROID DISEASE; VACUUM; VASCULAR SURGERY; VASODILATATION; VISUAL DISORDER; YAWNING;

EID: 33846039750     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666180-00006     Document Type: Review

References (98)

1. The Second International Consultation on Dysfunction. Sexual Medicine: Sexual Dysfunctions in Men and Women. 2004 Jun 28-Jul 1; Paris
2. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-3
3. Moreira Jr ED, Lbo CF, Diament A, et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431-6
4. Schouten BW, Bosch JL, Bernsen RM, et al. Incidence of clinical relevant erectile dysfunction (ED) and ED by two other common definitions: strong effect of definition and bias by duration follow-up. Int J Impot Res 2005; 17: 58-62
5. Kinsey AC, Pomeroy WB, Martin CE. Sexual behaviour of the human male. Philadelphia (PA): WB Saunders and Co, 1948
6. Shabsig R, Alexandre A, Bay Nielsen H, et al. Economic aspects of erectile dysfunction [abstract]. 1st International Consultation on Erectile Dysfunction; 1999 Jul 1-3; Paris. Plymouth: Plymbridge Distributors Ltd
7. Sexual Dysfunction Therapeutics. A market overview and therapeutics analysis 2002. San Mateo (CA): Frontline Strategic Consultation Inc., 2002
8. British National Formulary. No. 51 (Mar 2006). London: BMJ Publishing Group Ltd, 2006
9. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Imp Res 1999; 11: 141-4
10. Wespes E, Amar E, Hatzichristou D, et al. Guidelines of erectile dysfunction: European Association of Urology 2006 [online]. Available from URL: http://www.uroweb.org/index.php?.structure_id=140. [Accessed 2006 Aug 24]
11. Hengeveld MW. Erectile disorder: a psychosexological review. In: Jonas U, Thon WF, Stief CG, editors. Erectile dysfunction. Berlin: Springer Verlag, 1991
12. O'Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology 1995; 46: 782-3
13. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30
14. Althof SE, Corty EW, Morales SB, et al. Development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793-9
15. Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42
16. Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997; 9: 115-21
17. Ballard SA, Gingell JC, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum in vitro and on the activities of cyclic nucleotide phosphodiesterase isozyme. J Urol 1998; 159: 2164-71
18. Baxendale RW, Smith EJ, Stanley M, et al. Selectivity of sildenafil citrate and other phosphodiesterases type 5 inhibitors against phosphodiesterases types 7-11 [abstract]. J Clin Pharmacol 2001; 41: 1015
19. Saenz de Tejada I, Angula J, Cuevas P, et al. The phosphodiesterase inhibitor selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-90
20. Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J 2002; 4 Suppl. H: H7-12
21. Viagra®: summary of product characteristics [online]. Available from URL: http://pfizer.com/download/uspi_viagra.pdf. [Accessed 2006 May 4]
22. Cialis®: summary of product characteristics [online]. Available from URL: http://www.health.gov.il/units/pharmacy/trufot/alonim/1518.pdf [Accessed 2006 May 4]
23. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397-404
24. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 845-1039
25. Zelefsky MJ, Mckee AB, Lee H, et al. Efficacy of sildenafil in patients with erectile dysfunction after radiotherapy of the prostate. Urology 1999; 53: 775-8
26. Merrick GS, Butler WM, Lief JH, et al. Efficacy of sildenafil in prostate brachytherapy patients with erectile dysfunction. Urology 1999; 53: 1112-6
27. Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241-5
28. Sadovsky R, Miller T, Moskowitz M, et al. Three year update of sildenafil citrate (Viagra™) efficacy and safety. Int J Clin Prac 2001; 55: 115-28
29. Morales A, Gingell GC, Collins M, et al. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-73
30. Arruda Olson A, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 2002 287: 719-25
31. Hermann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. New Engl J Med 2000; 342: 1622-6
32. Fazio L, Brock G. Erectile dysfunction: management update. CMAJ 2004; 170: 1429-37
33. Hellstrom WG, Gittleman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized double-blind placebo controlled trial. J Androl 2002; 23: 763-72
34. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor improves erectile function in patients with diabetes mellitus. Proc Am Diabetic Assoc Jun 2001
35. Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278-83
36. Levitra®: summary of product characteristics [online]. Available from URL: http://www.levitra.co.uk/smpc.htm. [Accessed 2006 May 4]
37. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent highly selective phosphodiesterase inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardio 2002; 40: 2006-12
38. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1322-6
39. Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomised controlled trial. Urology 2003; 62: 121-5
40. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-8
41. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan and pharmacokinetic study. World J Urol 2001; 19: 32-9
42. Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no deleterious effect on spermatogenesis or reproductive hormones. J Urol 2003; 170: 887-91
43. Saenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile function in men with diabetes. Diabetes Care 2002; 25: 2159-64
44. Patterson D, Kloner R, Effron MB, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60: 459-68
45. Stroberg P, Yu CC, Su CC, et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724-37
46. von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomised, double-blind, cross-over study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-507
47. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomised, double blind, cross-over study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-23
48. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitor for erectile dysfunction. Eur Urol 2006; 49: 30-7
49. Eardley I, Mirone V, Montorsi F, et al. An open label, multicentre, randomised, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323-32
50. Dula E, Bukofzer S, Perdol R, et al. Double blind, crossover comparison of 3mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-64
51. Heaton JP. Key issues from clinical trial of apomorphine SL. Int J Impot Res 2000; Suppl. 4: S67-73
52. Eardley I, Wright P, Macdonagh R, et al. An open label, randomised, flexible dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004; 93: 1271-5
53. Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 274-9
54. Junemann KP, Manning M, Krautschik A, et al. 15 years of injection therapy in erectile dysfunction: a review [abstract]. Int J Impot Res 1996; 8: A60
55. Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly, nonpsychogenic erectile dysfunction with vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo controlled study. BJU Int 1999; 83: 274-9
56. VIVIUS Inc. MUSE® summary of product characteristics [online]. Available from URL: http://www.muserx.net/res/pack_inserts_PFI_1.3pdf [Accessed 2006 Nov 21]
57. Padma-Nathan H, Hellstrom W, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. New Eng J Med 1997; 336: 1-7
58. Williams G, Abbou CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction and their partners. Br J Urol 1998; 82: 847-54
59. Shabsigh R, Padma-Natham H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomised, crossover multicentre study. Urology 2000; 55: 109-13
60. Gauthier A, Rutchik DS, Winters CJ, et al. Relative efficacy of sildenafil compared to other treatment options for erectile dysfunction. South Med J 2000; 93: 962-5
61. Meyhoff H, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitrogylcerine. Br J Urol 1992; 69: 88-90
62. Goldstein I, Payton TR, Schecter PJ. A double blind, placebo controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan™) for in-office treatment of erectile dysfunction. Urology 2001; 57: 301-4
63. Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate and co-dergocrine mesylate. BMJ 1996; 312: 1512-5
64. Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764-7
65. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endcrinol Metab 1990; 71: 963-9
66. Tenover JL. Testosterone replacement therapy in older men. Int J Androl 1999; 22: 300-6
67. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006; 38: 61-8
68. Rosenthal BD, May NR, Metro MJ, et al. Adjuvant use of Androgel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006; 67: 571-4
69. Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 4: 559-4
70. Shabsigh R, Kaufman JM, Steidle C, et al. Randomised study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-63
71. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients. Endocr Pract 2002; 8: 439-56
72. Cookson MS, Nadig PW. Long-term results with vacuum constriction devices. J Urol 1993; 149: 290-4
73. Gilbert HW, Gingell JC. Vacuum constriction devices: second-line conservative treatment for impotence. Br J Urol 1992; 70: 81-3
74. Levine LA, Estrada CR, Morgentaler A. Mechanical reliability and safety of and patient satisfaction with Ambicor inflatable penile prosthesis: results of a two center study. J Urol 2001; 166: 932-7
75. Montorsi F, Rigatti P, Carmignani G, et al. AMS three piece inflatable implants for erectile dysfunction: a long-term multi-institutional trial studying 200 consecutive patients. Eur Urol 2000; 35: 50-5
76. Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700 CX inflatable penile prosthesis: results of long-term multi-center study. J Urol 2000; 164: 376-80
77. Montague DK, Angermeier KW, Lakin MM. Penile prosthesis infections. Int J Impot Res 2001; 13: 326-8
78. Wilson SK, Delk JR, Henry GD. Short term follow for enhanced American Medical Systems 700 CX prosthesis [abstract no. 600A]. J Urol 2002; 167 Suppl. 4
79. Wolter CE, Hellstrom WJ. The hydrophilic coated inflatable penile prosthesis: 1 year experience. J Sex Med 2004; 1: 221-4
80. Mulcahy JJ. Long-term experience with salvage of infected penile prosthesis. J Urol 2000; 163: 481-2
81. Fishman IJ, Scott FB, Selim A, et al. The rescue procedure: an alternative for managing infected penile prosthesis. Contemp Urol 1997; 11: 73-80
82. Kaufman JM, Kaufman JL, Borges FD. Immediate salvage procedure for infected penile prosthesis. J Urol 1998; 159: 816-9
83. Sharaby JS, Benet AE, Melman A. Revascularisation: a five year follow-up study [abstract]. J Urol 1995; 153: 369A
84. Konnak JW, Ohl DA. Microsurgical penile revascularisation using central corporeal penile artery. J Urol 1989; 142: 305-8
85. Depalma RG. Vascular surgery for impotence: a review. Int J Impot Res 1997; 9: 61-7
86. Rao DS, Donatucci CF. Vasculogenic impotence: arterial and venous surgery. Urol Clin NA 2001; 22: 309-19
87. Berradinucci C, Morales A, Heaton JP, et al. Surgical treatment of penile veno-occlusive dysfunction: is it justified? Urology 1997; 47: 88-92
88. Schultheiss D, Truss MC, Becker AJ, et al. Long-term results following dorsal penile ligation in 126 patients with veno-occlusive dysfunction. Int J Impot Res 1997; 9: 205-9
89. Lukkarinen O, Tontilla P, Hellstrom P, et al. Non prosthetic surgery in the treatment of erectile dysfunction. Scan J Urol Nephrol 1997; 32: 42-6
90. Arjona M, Osteros R, Zarca M, et al. Percutaneous embolisation for erectile dysfunction due to venous leakage: prognostic factors for good therapeutic results. Eur Urol 2001; 39: 15-9
91. Miwa Y, Shioyama R, Itou Y, et al. Pelvic venoablation with ethanol for the treatment of erectile dysfunction due to veno-occlusive dysfunction. Urology 2001; 58: 76-9
92. Peskircioglu L, Tekin I, Boyvat F, et al. Embolisation of the deep dorsal vein for the treatment of erectile impotence due to veno-occlusive dysfunction. J Urol 2000; 163: 472-5
93. Alossini G, Ficarra V, Cavalleri S, et al. Long-term results of veno-occlusive percutaneous treatment of erectile disorders of venous origin. Arch Ital Androl 1998; 70: 203-9
94. Martinez Portillo FJ, Junemann KP, Sohn M. Surgical therapy of erectile dysfunction: current status [in German]. Urologe A 2003; 42: 1337-44
95. Dorey G, Speakman MJ, Feneley RCL, et al. Pelvic floor exercises for erectile dysfunction. BJU Int 2005; 96: 595-7
96. Masters WH, Johnson VE. Human sexual inadequacy. London: Churchill, 1970
97. Hawton K, Catalan J. Prognostic factors in sex therapy. Behav Sex Ther 1986; 24: 377-85
98. Barnes P. Role of sex therapy in the management of ED. In: Kirby RS, Carson C, Webster GD, editors. Impotence diagnosis and management of male ED. Oxford: Butterworth-Heinemann, 1991